Tokyo-based Olympus says the EU-ME3 addresses needs of healthcare professionals for high-quality images during endoscopic ultrasounds. The company plans to launch the system in Europe, the Middle East, Africa, parts of Asia and Oceana during this fiscal year.
Olympus’ technology assists in the diagnosis of lesions in the pancreas and the bile ducts. It also helps locate lesions deep inside the body that remain invisible to gastrointestinal endoscopes.
The company said it also enhances examinations for pancreatitis, pancreatic cancer and the diagnosis of cancer invasion in the stomach and esophagus. It can also help facilitate the visualization of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA). This assists in early, minimally invasive diagnosis and lung cancer staging.
“It is said that pancreatic cancer is difficult to be detected in its early stages, and that lung cancer has the highest mortality rate among all cancers,” said Hironobu Kawano, head of the endoscopic solutions division at Olympus. “With the launch of the EU-ME3, Olympus aims to enhance the standard of care including these diseases and to further improve the quality of life of patients.”
Olympus touts the image quality and functionality provided by EU-ME3. Its new shear wave quantification feature contributes to accurate diagnosis, too. It provides quantitative information on the stiffness of tumor and inflamed lesions. Olympus says this represents an important factor in diagnosing a degree of pancreatitis and the malignancy of pancreatic cancer.
It features multiple software options for individual clinical needs, too. Olympus said this backs its aim to stay flexible in the selection of functions, tailoring EU-ME3 based on specialty. It also includes a backlit keyboard with a large touch panel and trackpad. This facilitates better operability and easier cleaning.